Nothing Special   »   [go: up one dir, main page]

AR082153A1 - N-sulfonilbenzamidas utiles como inhibidor del canal de sodio - Google Patents

N-sulfonilbenzamidas utiles como inhibidor del canal de sodio

Info

Publication number
AR082153A1
AR082153A1 ARP110102490A ARP110102490A AR082153A1 AR 082153 A1 AR082153 A1 AR 082153A1 AR P110102490 A ARP110102490 A AR P110102490A AR P110102490 A ARP110102490 A AR P110102490A AR 082153 A1 AR082153 A1 AR 082153A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
independently
cycloalkyl
alkyl
het2
Prior art date
Application number
ARP110102490A
Other languages
English (en)
Inventor
Nunzio Sciammetta
Robert Ian Storer
Nigel Alan Swain
Andrew Simon Bell
Alan Daniel Brown
Groot Marcel John De
Steven Matthieu Gaulier
Russell Andrew Lewthwaite
Ian Roger Marsh
David Simon Millan
Pacheco Manuel Perez
David James Rawson
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR082153A1 publication Critical patent/AR082153A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los inhibidores de Nav1.7 son potencialmente útiles para el tratamiento de un amplio rango de trastornos, en particular, del dolor.Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o su sal farmacéuticamente aceptable, en donde X es O, S, NH, o CH2; Het1 es (i) un heteroarilo de 9 ó 10 miembros que comprende de 1 a 3 átomos de nitrógeno; o (ii) un heteroarilo de 6, 9 ó 10 miembros que comprende de 1 a 3 átomos de nitrógeno cuyo heteroarilo se sustituye, independientemente, con 1 a 3 sustituyentes seleccionados de Y1 e Y2; Y1 e Y2 se seleccionan, independientemente, de F; Cl; CN; NO2; alquilo C1-8, opcionalmente sustituido con cicloalquilo C3-8 y/o, si lo permite la valencia, con 1 a 8 F; cicloalquilo C3-8, opcionalmente sustituido, si lo permite la valencia, con 1 a 8 F; NR7R8; alquiloxi C1-8, opcionalmente sustituido, de forma independiente, con 1 a 3 R9, o, si lo permite la valencia, con 1 a 8 F; cicloalquiloxi C3-8, opcionalmente sustituido, silo permite la valencia, con 1 a 8 F; fenilo, opcionalmente sustituido, en forma independiente, con 1 a 3 R10; fenoxi, opcionalmente sustituido, en forma independiente, con 1 a 3 R10; Het2, Het2-oxi; y Het3; en donde cicloalquiloxi C3-8 puede fusionarse opcionalmente a un anillo de fenilo o puede sustituirse independientemente con 1 a 3 R10; R1 es alquilo C1-6 o cicloalquilo C3-8, cada uno de los cuales se sustituye opcionalmente, silo permite la valencia, con 1 a 8 F; R2, R3, R4 son, independientemente, H, F, Cl u -OCH3; R5 es H, CN, F, Cl o R6; R6 es un grupo seleccionado de alquilo C1-6 y alquiloxi C1-6, en donde cada grupo se sustituye, opcionalmente, si lo permite la valencia, con 1 a 8 F; R7 y R8 son, independientemente, H; alquilo C1-8, opcionalmente sustituido, en forma independiente, con 1 a 3 R11; cicloalquilo C3-8, opcionalmente sustituido, si lo permite la valencia, con 1 a 8 F; Het2 “unido a C” o Het3 “unido a C”; en donde cicloalquilo C3-8 puede fusionarse opcionalmente a un anillo de fenilo o puede sustituirse independientemente, si lo permite la valencia, con 1 a 8 F y/o con 1 a 3 R10; o R7 y R8, junto con el átomo de nitrógeno al que están unidos, forman un anillo de 7 a 9 miembros en puente, saturado; R9 es alquiloxi C1-6; cicloalquilo C3-8, opcionalmente sustituido con 1 a 3 F o alquilo C1-6; Het2 o fenilo, opcionalmente sustituido, en forma independiente, con 1 a 3 R6; R10 es Cl, CN o R6; R11 es F; alquiloxi C1-6; cicloalquilo C3-8, opcionalmente sustituido con 1 a 3 F; Het2 “unido a C”; o fenilo, opcionalmente sustituido, en forma independiente, con 1 a 3 R6; Het2 es un monoheterocicloalquilo saturado de 3 a 8 miembros que comprende 1 ó 2 miembros del anillo seleccionados de -NR12- y -O-, en donde dicho monoheterocicloalquilo se sustituye, opcionalmente, en un átomo de carbono del anillo con 1 a 3 sustituyentes seleccionados, independientemente, de F, alquilo C1-6, alquiloxi C1-4-alquileno C0-4 y cicloalquilo C3-8; Het3 es un heteroarilo de 5 ó 6 miembros que comprende de 1 a 3 átomos de nitrógeno, en donde dicho heteroarilo se sustituye, opcionalmente, con 1 a 3 sustituyentes seleccionados de F, Cl, CN y R6; y R12 es H, alquilo C1-6 o cicloalquilo C3-8, en donde alquilo C1-6 y cicloalquilo C3-8 se sustituye, opcionalmente, con 1 a 3 F; o, cuando Het2 está “unido a N”, está ausente.
ARP110102490A 2010-07-12 2011-07-11 N-sulfonilbenzamidas utiles como inhibidor del canal de sodio AR082153A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36336510P 2010-07-12 2010-07-12
US201161477897P 2011-04-21 2011-04-21
US201161491659P 2011-05-31 2011-05-31

Publications (1)

Publication Number Publication Date
AR082153A1 true AR082153A1 (es) 2012-11-14

Family

ID=44477684

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102490A AR082153A1 (es) 2010-07-12 2011-07-11 N-sulfonilbenzamidas utiles como inhibidor del canal de sodio

Country Status (8)

Country Link
US (1) US8592629B2 (es)
EP (1) EP2593432B1 (es)
JP (1) JP2013532184A (es)
AR (1) AR082153A1 (es)
CA (1) CA2801032A1 (es)
ES (1) ES2525581T3 (es)
UY (1) UY33501A (es)
WO (1) WO2012007861A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004706A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
EP2593427B1 (en) 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2800971A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
EP2773637B1 (en) 2011-10-31 2016-06-08 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JP6067031B2 (ja) * 2012-01-04 2017-01-25 ファイザー・リミテッドPfizer Limited N−アミノスルホニルベンズアミド
PE20150400A1 (es) * 2012-05-22 2015-03-27 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
AR095192A1 (es) * 2013-01-31 2015-09-30 Vertex Pharma Quinolina y quinazolinamidas como modulares de canales de sodio
US8877766B2 (en) * 2013-02-15 2014-11-04 Peter F. Kador Neuroprotective multifunctional antioxidants and their monofunctional analogs
BR112015022488A2 (pt) 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
PE20161247A1 (es) * 2013-11-27 2016-11-30 Genentech Inc Benzamidas sustituidas y metodos para usarlas
EP4290892A3 (en) 2014-04-09 2024-01-24 Shifman, Orit Methods, platforms and systems for paying persons for use of their personal intelligence profile data
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
CN104557924B (zh) * 2015-01-14 2016-05-04 福州大学 一种氟代烷基醚铜(i)及其制备方法与应用
CN107428683B (zh) * 2015-02-04 2020-06-02 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
MA41803A (fr) * 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
AU2016330503B2 (en) 2015-09-28 2021-04-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2017082688A1 (ko) * 2015-11-13 2017-05-18 주식회사 대웅제약 소디움 채널 차단제
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
JP6837052B2 (ja) * 2016-03-09 2021-03-03 日本曹達株式会社 ピリジン化合物およびその用途
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
US10668067B2 (en) * 2016-07-20 2020-06-02 Amgen Inc. Pyridine sulfonamides
WO2018072602A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
LT3448859T (lt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Pirolpirolo kompozicijos, kaip piruvato kinazės (pkr) aktyvatoriai
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック, インコーポレイテッド ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体
CN112041313A (zh) 2018-02-26 2020-12-04 基因泰克公司 吡啶-磺酰胺化合物及其针对疼痛和相关疾患的用途
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
EP3955920A1 (en) * 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
CN111978245A (zh) * 2020-09-15 2020-11-24 上海毕得医药科技有限公司 一种3-氟-2-异丁基吡啶的制备方法
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0003416B1 (en) 1978-01-19 1981-08-26 Imperial Chemical Industries Plc Diphenyl ether compounds useful as herbicides; methods of using them, processes for preparing them, and herbicidal compositions containing them
EP0023100B1 (en) 1979-07-18 1982-11-10 Imperial Chemical Industries Plc Herbicidal compositions comprising a diphenyl ether compound in admixture with another herbicide
GR71915B (es) 1979-11-27 1983-08-16 Pfizer
US4744818A (en) 1981-07-27 1988-05-17 Rhone-Poulenc Agrochimie Herbicidal N-halo-5(substituted-phenoxy or -pyridyloxy)-2-substituted benzoic acid sulfonamides and sulfamates
EP0194599A3 (en) 1985-03-14 1988-01-20 Nissan Chemical Industries Ltd. Benzamide derivatives, process for producing the same, and soil fungicides containing the same
EP0322413A4 (en) 1986-08-20 1989-10-04 Fmc Corp WEED KILLER.
US5084085A (en) 1986-08-20 1992-01-28 Fmc Corporation Herbicidal aryloxyphenyltriazolinones and related compounds
US4845264A (en) 1987-03-05 1989-07-04 Teijin Limited Phenoxycarboxylic acid and herbicide comprising it as active ingredient
US4920132A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920133A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920131A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
DE68909958D1 (de) 1988-01-19 1993-11-25 Tanabe Seiyaku Co Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung.
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
AP161A (en) 1989-08-11 1991-12-20 Ici Plc Novel Quinoline derivatives.
US4945113A (en) 1989-09-29 1990-07-31 Uniroyal Chemical Company, Inc. herbicidal sulfonamide derivatives
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
GB2266527A (en) 1992-03-17 1993-11-03 Merck & Co Inc Substituted azetidinones useful in the treatment of leukemia
JPH05289262A (ja) 1992-04-10 1993-11-05 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH05307242A (ja) 1992-04-28 1993-11-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JP3101848B2 (ja) 1992-05-15 2000-10-23 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
FR2694295B1 (fr) 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
AU5802894A (en) 1992-12-17 1994-07-04 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0617001B1 (en) 1993-03-19 2000-01-26 Merck & Co. Inc. Phenoxyphenylacetic acid derivatives
JPH06347968A (ja) 1993-04-14 1994-12-22 Fuji Photo Film Co Ltd ハロゲン化銀感光材料
JP3503839B2 (ja) 1994-05-25 2004-03-08 富士写真フイルム株式会社 ポジ型感光性組成物
CA2195758A1 (en) 1994-08-08 1996-02-22 Scott W. Bagley Phenoxyphenylacetic acid derivatives
WO1996009818A1 (en) 1994-09-27 1996-04-04 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB9514031D0 (en) 1995-07-10 1995-09-06 Zeneca Ltd Chemical process
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JP3519218B2 (ja) 1996-08-14 2004-04-12 富士写真フイルム株式会社 ハロゲン化銀写真感光材料および画像形成方法
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU745081B2 (en) 1997-06-27 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
US6555584B1 (en) 2000-06-29 2003-04-29 Ajinomoto Co., Inc. Acylsulfonamide derivative
DE19742951A1 (de) 1997-09-29 1999-04-15 Hoechst Schering Agrevo Gmbh Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung
CN1302206A (zh) 1997-10-17 2001-07-04 阿温蒂斯药物制品公司 喹啉衍生物的治疗用途
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
KR100693771B1 (ko) 1999-04-28 2007-03-12 사노피-아벤티스 도이칠란트 게엠베하 Ppar 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
WO2000066120A1 (en) 1999-05-05 2000-11-09 Merck & Co., Inc. Novel catechols as antimicrobial agents
JP2001075213A (ja) * 1999-09-07 2001-03-23 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤、その製造方法及びこれを用いたハロゲン化銀写真感光材料
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
JP2004500389A (ja) 2000-03-09 2004-01-08 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Pparメディエーターの治療での使用
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
PT1445249E (pt) 2001-11-16 2013-01-16 Toyama Chemical Co Ltd Novos derivados de benzofenona ou os seus sais
WO2004018386A2 (en) 2002-08-26 2004-03-04 Merck & Co., Inc. Acetophenone potentiators of metabotropic glutamate receptors
AR045238A1 (es) 2003-08-08 2005-10-19 Vertex Pharma Compuestos utiles como inhibidores de canales ionicos regulados por voltaje
JP4898458B2 (ja) 2004-02-12 2012-03-14 トランス テック ファーマ,インコーポレイテッド 置換アゾール誘導体、組成物及び使用方法
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
WO2006015158A1 (en) 2004-07-30 2006-02-09 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
PT1802579E (pt) 2004-10-20 2014-02-17 Merck Serono Sa Derivados da 3-arilaminopiridina
JP2008189549A (ja) 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
RS20090154A (en) 2006-10-18 2010-10-31 Pfizer Products Inc. Biaryl ether urea compounds
JP5236664B2 (ja) 2007-02-01 2013-07-17 レスバーロジックス コーポレイション 心血管疾患を予防および治療するための化合物
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
NZ581614A (en) 2007-05-03 2011-06-30 Pfizer Ltd 2-pyridine carboxamide derivatives as sodium channel modulators
TW200911245A (en) 2007-06-07 2009-03-16 Astellas Pharma Inc Pyridone derivatives
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン, インコーポレイテッド ナトリウムチャネル阻害物質
JP5436434B2 (ja) * 2007-10-11 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なアミド
UY31468A1 (es) 2007-11-15 2009-07-17 Derivados bis-(sulfonilamino) en terapia 065
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
US20090291921A1 (en) 2007-11-20 2009-11-26 Gilead Sciences, Inc. Integrase inhibitors
EP2222639A1 (en) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
GB0725214D0 (en) 2007-12-24 2008-02-06 Karobio Ab Pharmaceutical compounds
TW201010976A (en) 2008-06-23 2010-03-16 Astellas Pharma Inc Sulfonamide compounds or salts thereof
US8107894B2 (en) 2008-08-12 2012-01-31 Raytheon Company Modular solid-state millimeter wave (MMW) RF power source
MA32965B1 (fr) 2009-01-12 2012-01-02 Pfizer Ltd Derives de sulfonamides
JP5289262B2 (ja) 2009-09-30 2013-09-11 京セラドキュメントソリューションズ株式会社 シート搬送装置とこれを備えた画像読取装置及び画像形成装置
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
WO2012004706A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
EP2593427B1 (en) * 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2800971A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物

Also Published As

Publication number Publication date
UY33501A (es) 2012-02-29
CA2801032A1 (en) 2012-01-19
EP2593432A1 (en) 2013-05-22
JP2013532184A (ja) 2013-08-15
ES2525581T3 (es) 2014-12-26
EP2593432B1 (en) 2014-10-22
US20120010183A1 (en) 2012-01-12
US8592629B2 (en) 2013-11-26
WO2012007861A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
AR082153A1 (es) N-sulfonilbenzamidas utiles como inhibidor del canal de sodio
AR082201A1 (es) Bencenosulfonamidas utiles como inhibidores del canal de sodio
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR071617A1 (es) Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
MY177250A (en) Novel nicotinamide derivative or salt thereof
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
NZ610312A (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
CO5611128A2 (es) Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales
ES2620379T3 (es) Quinolina y quinoxalina amidas como moduladores de canales de sodio
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
SI2751083T1 (en) Quinolone compound
AR077548A1 (es) Inhibidores del virus de la hepatitis c
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
ECSP11010901A (es) Compuestos de amida útiles en terapia
AR056519A1 (es) 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal